Trials / Completed
CompletedNCT03711604
Compassionate Use Study of Tenalisib (RP6530)
An Open Label, Compassionate Use Study of Tenalisib (RP6530) in Patients Currently Receiving Treatment on Tenalisib Trials in Hematological Malignancies
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Rhizen Pharmaceuticals SA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Tenalisib has been evaluated as an investigational new drug in number of early clinical studies in patients with relapsed/refractory hematological malignancies and demonstrated acceptable safety and promising efficacy in these patients. Since these advanced relapsed/refractory patients have limited therapeutic options, it is reasonable to continue Tenalisib in responding patients post completion of their participation in previous clinical studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenalisib | BID Orally |
Timeline
- Start date
- 2018-11-28
- Primary completion
- 2023-03-25
- Completion
- 2023-03-25
- First posted
- 2018-10-18
- Last updated
- 2024-05-08
- Results posted
- 2024-05-08
Locations
7 sites across 3 countries: United States, Georgia, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03711604. Inclusion in this directory is not an endorsement.